Logo image of ALCJ.PA

CROSSJECT (ALCJ.PA) Stock Price, Quote, News and Overview

EPA:ALCJ - Euronext Paris - Matif - FR0011716265 - Common Stock - Currency: EUR

1.97  +0.01 (+0.41%)

ALCJ.PA Quote, Performance and Key Statistics

CROSSJECT

EPA:ALCJ (3/7/2025, 7:00:00 PM)

1.97

+0.01 (+0.41%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Supplies
Statistics
52 Week High3.7
52 Week Low1.52
Market Cap91.07M
Shares46.23M
Float36.04M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE5.7
Earnings (Next)03-31 2025-03-31/amc
IPO02-20 2014-02-20


ALCJ.PA short term performance overview.The bars show the price performance of ALCJ.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10

ALCJ.PA long term performance overview.The bars show the price performance of ALCJ.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of ALCJ.PA is 1.97 EUR. In the past month the price increased by 4.56%. In the past year, price decreased by -42.73%.

CROSSJECT / ALCJ Daily stock chart

ALCJ.PA Competitors/Peers

The largest stocks on the EU markets in the "Health Care Supplies" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
EL.PA ESSILORLUXOTTICA 53.13 124.44B
ESL.DE ESSILORLUXOTTICA 53.09 124.35B
1EL.MI ESSILORLUXOTTICA 52.97 124.08B
CBHD.DE COLOPLAST-B 33.98 21.00B
GENT.OL GENTIAN DIAGNOSTICS ASA 16.31 721.66M
GBT.PA GUERBET 10.23 341.28M
PTP.DE PENTIXAPHARM HOLDING AG N/A 89.03M
AFME.PA AFFLUENT MEDICAL SA N/A 55.09M
SVS.MI SVAS BIOSANA SPA 7.25 41.44M
IVN.MI IVISION TECH SPA N/A 16.85M

About ALCJ.PA

Company Profile

ALCJ logo image Crossject SA manufactures and markets needle free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 110 full-time employees. The company went IPO on 2014-02-20. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The firm has industrial partnerships with Hirtenberger and Recipharm. The company provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.

Company Info

CROSSJECT

Parc Mazen-Sully, 6 Rue Pauline Kergomard

Dijon BOURGOGNE-FRANCHE-COMTE FR

Employees: 105

Company Website: https://www.crossject.com

Investor Relations: http://www.crossject.com/rapports-financiers-et-documents-de-r%C3%A9f%C3%A9rence/

Phone: 33380549850

CROSSJECT / ALCJ.PA FAQ

What is the stock price of CROSSJECT today?

The current stock price of ALCJ.PA is 1.97 EUR. The price increased by 0.41% in the last trading session.


What is the ticker symbol for CROSSJECT stock?

The exchange symbol of CROSSJECT is ALCJ and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALCJ.PA stock listed?

ALCJ.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for CROSSJECT stock?

9 analysts have analysed ALCJ.PA and the average price target is 4.13 EUR. This implies a price increase of 109.7% is expected in the next year compared to the current price of 1.97. Check the CROSSJECT stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CROSSJECT worth?

CROSSJECT (ALCJ.PA) has a market capitalization of 91.07M EUR. This makes ALCJ.PA a Micro Cap stock.


How many employees does CROSSJECT have?

CROSSJECT (ALCJ.PA) currently has 105 employees.


What are the support and resistance levels for CROSSJECT (ALCJ.PA) stock?

CROSSJECT (ALCJ.PA) has a support level at 1.78 and a resistance level at 2.18. Check the full technical report for a detailed analysis of ALCJ.PA support and resistance levels.


Is CROSSJECT (ALCJ.PA) expected to grow?

The Revenue of CROSSJECT (ALCJ.PA) is expected to grow by 3.06% in the next year. Check the estimates tab for more information on the ALCJ.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CROSSJECT (ALCJ.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CROSSJECT (ALCJ.PA) stock pay dividends?

ALCJ.PA does not pay a dividend.


When does CROSSJECT (ALCJ.PA) report earnings?

CROSSJECT (ALCJ.PA) will report earnings on 2025-03-31, after the market close.


What is the Price/Earnings (PE) ratio of CROSSJECT (ALCJ.PA)?

CROSSJECT (ALCJ.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).


ALCJ.PA Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to ALCJ.PA. When comparing the yearly performance of all stocks, ALCJ.PA is a bad performer in the overall market: 93.92% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALCJ.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ALCJ.PA. Both the profitability and financial health of ALCJ.PA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALCJ.PA Financial Highlights

Over the last trailing twelve months ALCJ.PA reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS decreased by -1.92% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -31.63%
ROE -593.99%
Debt/Equity 11.67
Chartmill High Growth Momentum
EPS Q2Q%-29.25%
Sales Q2Q%N/A
EPS 1Y (TTM)-1.92%
Revenue 1Y (TTM)-71%

ALCJ.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to ALCJ.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of 33.19% and a revenue growth 3.06% for ALCJ.PA


Ownership
Inst Owners0.4%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts84.44
Price Target4.13 (109.64%)
EPS Next Y33.19%
Revenue Next Year3.06%